Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis

<bold>Objectives:</bold> Clinical Remission (CR) is an emerging goal in asthma assessed after 52 weeks of therapy. There is evidence for CR in patients receiving biologics but data for patients on inhaled maintenance therapy is needed. This post hoc analysis of CAPTAIN assessed characteristics of patients who met CR components at Week 24 (w24). <bold>Methods:</bold> CAPTAIN compared FF/UMEC/VI vs FF/VI in adults with uncontrolled moderate–severe asthma despite ICS/LABA; history of severe exacerbation was not required in the prior year. CR was defined as no systemic corticosteroid use, no severe exacerbations, ACQ-5 ≤1.5, lung function optimisation (change in trough FEV₁ ≥100mL). Characteristics of patients meeting CR components at w24 for FF/UMEC/VI 100/62.5/25µg (N=406) or 200/62.5/25µg (N=408) were assessed. <bold>Results:</bold> Patient characteristics were similar between FF/UMEC/VI doses. Those who met CR components were slightly more likely to have lower ACQ-5 scores and BMI, and <2 severe exacerbations in the year prior to randomisation (<bold>Table</bold>). <bold>Conclusions:</bold> Patients with uncontrolled moderate–severe asthma despite ICS/LABA can meet CR components at w24 with FF/UMEC/VI. Patients not meeting CR components were more likely to have worse disease control, higher BMI and history of ≥2 exacerbations (in the year prior). Early intervention and therapeutic review may be needed to ensure CR becomes embedded as a proactive goal. <bold>Funding:</bold> GSK (205715/<ext-link>NCT02924688</ext-link>) <fig><object-id>erj;64/suppl_68/PA1197/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>